In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz Pharmaceuticals: The Concept Bet, at a Whole New Level

Executive Summary

The press around the size of Jazz Pharmaceuticals' $250 million private financing has obscured the whole point: the company and the financing represent a fundamentally different business model for biopharmaceutical investing and companies: betting on product concepts--not products and not technology.

You may also be interested in...



Jazz Pharmaceuticals Improvises Its Way To A Turnaround

A day after specialty drug developer Jazz Pharmaceuticals Inc. announced plans to merge with Irish drugmaker Azur Pharma Ltd. in mid-September, the company had something new to celebrate. Jazz’s stock price reached an all-time high of $47.88 per share, giving the company a market valuation of almost exactly $2 billion.

Private Equity Comes to Discovery

Through what could be a $550 million investment, Invus wants to play for Lexicon the role Roche has played for Genentech, enabling the biotech to finance both its more advanced projects and its discovery programs-something it couldn't do with smaller public market offerings or with lower-value deals on early-stage programs. The financial lynchpin for Invus: the huge prices Big Pharma is willing to pay for Phase II products. Will other private-equity firms follow Invus' lead?

Big Pharma's Biggest Drug Delivery Experiment: Johnson & Johnson

J&J has been Big Pharma's most aggressive experimenter with the drug-delivery and formulations world, but its two biggest transactions haven't provided the value J&J had originally hoped for.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel